HC
AQST icon

Hurley Capital’s Aquestive Therapeutics AQST Stock Holding History

Hurley Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.53K Buy
+1,569
New +$6.6K ﹤0.01% 381
2026
Q1 		– Sell
-1,569
Closed -$10.1K – 679
2025
Q4 		$10.1K Hold
1,569
– – 0.01% 330
2025
Q3 		$8.77K Hold
1,569
– – ﹤0.01% 378
2025
Q2 		$5.19K Hold
1,569
– – ﹤0.01% 366
2025
Q1 		$4.55K Hold
1,569
– – ﹤0.01% 383
2024
Q4 		$5.62K Buy
+1,569
New +$7.24K ﹤0.01% 323

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Hurley Capital's AQST Position: Q2 2026 in Review

Hurley Capital opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 1,569 shares worth $6.53K. The stake represents ﹤0.01% of the portfolio and ranks #381 among its holdings. This is a return to the name: Hurley Capital previously reported a position in AQST as recently as Q4 2025.

Hurley Capital first reported a position in AQST in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.1K in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Hurley Capital held 1,569 shares of Aquestive Therapeutics worth $6.53K as of Q2 2026.
  • Aquestive Therapeutics was a new Hurley Capital position in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #381 holding.
  • Hurley Capital first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Hurley Capital's Aquestive Therapeutics position peaked at $10.1K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.